Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03155061 |
TitleStudy of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2017-05-16 |
地点
日本
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
ONO-4538, ONO-4578, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT02925234 |
Title药物再发现方案（DRUP 试验） | 阶段
第二阶段
|
Date Added 2016-10-05 |
地点
荷兰
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04085185 |
Title评估 IBI110 对晚期恶性肿瘤患者的安全性、耐受性和初步疗效的研究 | 阶段
第 1 阶段
|
Date Added 2019-09-11 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
IBI110, IBI110+ Sintilimab, IBI110, Sintilinab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02617277 |
TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | 阶段
第 1 阶段
|
Date Added 2015-11-30 |
地点
Colorado, United States
Florida, United States Tennessee, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
AZD1775, MEDI4736 |
标签
MSS/ MMRp
|
| NCT ID NCT04550897 |
Title结直肠癌患者使用 BM7PE 免疫毒素的 I/II 期研究 | 阶段
第 1 阶段
|
Date Added 2020-09-16 |
地点
挪威
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
BM7PE |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03368963 |
TitleTAS102 与 NAL-IRI 联合治疗晚期消化道癌症 | 阶段
Phase 1, Phase 2
|
Date Added 2017-12-11 |
地点
Georgia, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05291156 |
TitleCAVE-2 GOIM 研究：阿韦鲁单抗加西妥昔单抗联合疗法作为再挑战策略的临床研究 | 阶段
第二阶段
|
Date Added 2022-03-22 |
地点
意大利
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Avelumab, cetuximab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03476681 |
TitleNEO-201 在实体瘤中的研究扩增队列 | 阶段
Phase 1, Phase 2
|
Date Added 2018-03-26 |
地点
Maryland, United States
Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
NEO-201 in combination with pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID VAPER |
TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer | 阶段
第 1 阶段
|
Date Added 2015-11-17 |
地点 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Celecoxib, Cyclophosphamide, imiquimod, vaccine |
标签
MSS/ MMRp
|
| NCT ID NCT03502733 |
TitleTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | 阶段
第 1 阶段
|
Date Added 2018-04-19 |
地点
Maryland, United States
Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo |
标签
MSS/ MMRp
|
